Author:
Lu Shun,Wu Lin,Jian Hong,Chen Ying,Wang Qiming,Fang Jian,Wang Ziping,Hu Yanping,Sun Meili,Han Liang,Miao Liyun,Ding Cuimin,Cui Jiuwei,Li Baolan,Pan Yueyin,Li Xingya,Ye Feng,Liu Anwen,Wang Ke,Cang Shundong,Zhou Hui,Sun Xing,Ferry David,Lin Yong,Wang Shuyan,Zhang Wen,Zhang Chengli
Funder
National Natural Science Foundation of China
Innovent Biologics
Reference30 articles.
1. Non-small cell lung cancer, version 3.2022. NCCN Clinical Practice Guidelines in Oncology;Ettinger;J Natl Compr Canc Netw,2022
2. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung;Han;J Clin Oncol,2012
3. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017
4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018
5. Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm);Lu;Proc Am Soc Clin Oncol,2021
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献